MCID: PDG001
MIFTS: 15

Pdgfra-Associated Chronic Eosinophilic Leukemia

Categories: Cancer diseases

Aliases & Classifications for Pdgfra-Associated Chronic Eosinophilic Leukemia

MalaCards integrated aliases for Pdgfra-Associated Chronic Eosinophilic Leukemia:

Name: Pdgfra-Associated Chronic Eosinophilic Leukemia 25 69
Pdgfra-Associated Myeloproliferative Neoplasm 25

Classifications:



Summaries for Pdgfra-Associated Chronic Eosinophilic Leukemia

Genetics Home Reference : 25 PDGFRA-associated chronic eosinophilic leukemia is a form of blood cell cancer characterized by an elevated number of cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRA-associated chronic eosinophilic leukemia.

MalaCards based summary : Pdgfra-Associated Chronic Eosinophilic Leukemia, also known as pdgfra-associated myeloproliferative neoplasm, is related to leukemia and chronic eosinophilic leukemia. The drugs glucocorticoids and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver.

Related Diseases for Pdgfra-Associated Chronic Eosinophilic Leukemia

Diseases related to Pdgfra-Associated Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 leukemia 9.9
2 chronic eosinophilic leukemia 9.9

Symptoms & Phenotypes for Pdgfra-Associated Chronic Eosinophilic Leukemia

Drugs & Therapeutics for Pdgfra-Associated Chronic Eosinophilic Leukemia

Drugs for Pdgfra-Associated Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 glucocorticoids Phase 4,Phase 2,Phase 1
2
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
3
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 1,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2 24280-93-1 446541
5
Ephedrine Approved Phase 3 299-42-3 9294
6
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 22916-47-8 4189
7
Pseudoephedrine Approved Phase 3 90-82-4 7028
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
10
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
11
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
12
Morphine Approved, Investigational Phase 3 57-27-2 5288826
13
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
14
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
15
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
16
Norgestimate Approved Phase 3 35189-28-7 6540478
17
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Analgesics Phase 3
20 Anesthetics Phase 3
21 Anesthetics, Dissociative Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
25 Excitatory Amino Acid Antagonists Phase 3
26 Excitatory Amino Acids Phase 3
27 Neurotransmitter Agents Phase 3,Phase 2
28 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
31 Dermatologic Agents Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
36 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
37 Calcium, Dietary Phase 3,Phase 1,Phase 2
38 Antifungal Agents Phase 3,Phase 1,Phase 2
39 Anti-Infective Agents Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 3,Phase 2,Phase 1
41 Cyclosporins Phase 3,Phase 1,Phase 2
42 Nasal Decongestants Phase 3
43 Ophthalmic Solutions Phase 3,Phase 1,Phase 2
44 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
45 Respiratory System Agents Phase 3,Phase 2
46 Tetrahydrozoline Phase 3,Phase 1,Phase 2
47 Vasoconstrictor Agents Phase 3
48 Analgesics, Opioid Phase 3
49 Narcotics Phase 3
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 119)

id Name Status NCT ID Phase Drugs
1 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
4 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
5 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
8 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
11 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
13 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
14 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
16 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
17 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
18 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
19 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
20 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
21 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
22 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
23 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
24 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
25 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
26 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant Completed NCT00530218 Phase 2 ganciclovir
27 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
28 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
29 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
30 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
31 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
32 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
33 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
34 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
35 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
36 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
37 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
38 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
39 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
40 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
41 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
42 Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer Active, not recruiting NCT00134017 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
43 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
44 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
45 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer Terminated NCT00295880 Phase 1, Phase 2
47 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
48 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
49 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
50 Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus

Search NIH Clinical Center for Pdgfra-Associated Chronic Eosinophilic Leukemia

Genetic Tests for Pdgfra-Associated Chronic Eosinophilic Leukemia

Anatomical Context for Pdgfra-Associated Chronic Eosinophilic Leukemia

MalaCards organs/tissues related to Pdgfra-Associated Chronic Eosinophilic Leukemia:

39
Bone, Bone Marrow, Liver, Eye, Myeloid, T Cells, Kidney

Publications for Pdgfra-Associated Chronic Eosinophilic Leukemia

Articles related to Pdgfra-Associated Chronic Eosinophilic Leukemia:

id Title Authors Year
1
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in china. ( 27120808 )
2016

Variations for Pdgfra-Associated Chronic Eosinophilic Leukemia

Expression for Pdgfra-Associated Chronic Eosinophilic Leukemia

Search GEO for disease gene expression data for Pdgfra-Associated Chronic Eosinophilic Leukemia.

Pathways for Pdgfra-Associated Chronic Eosinophilic Leukemia

GO Terms for Pdgfra-Associated Chronic Eosinophilic Leukemia

Sources for Pdgfra-Associated Chronic Eosinophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....